Rituximab Administration Following Autologous Stem Cell Transplant for Multiple Myeloma Is Associated with Severe IgM Deficiency

MLA

William V. Esler, et al. “Rituximab Administration Following Autologous Stem Cell Transplant for Multiple Myeloma Is Associated with Severe IgM Deficiency.” Blood, vol. 104, Nov. 2004, p. 4897. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........524b1128c5dcdf6782a6817bd83e3ae4&authtype=sso&custid=ns315887.

APA

William V. Esler, Phillip O. Periman, Rupa Varadarajan, Zhiqing Wang, Yana Zhang, & Seah H. Lim. (2004). Rituximab Administration Following Autologous Stem Cell Transplant for Multiple Myeloma Is Associated with Severe IgM Deficiency. Blood, 104, 4897.

Chicago

William V. Esler, Phillip O. Periman, Rupa Varadarajan, Zhiqing Wang, Yana Zhang, and Seah H. Lim. 2004. “Rituximab Administration Following Autologous Stem Cell Transplant for Multiple Myeloma Is Associated with Severe IgM Deficiency.” Blood 104 (November): 4897. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........524b1128c5dcdf6782a6817bd83e3ae4&authtype=sso&custid=ns315887.